Want to see ARQT full AI Analyst Report?
Arcutis Biotherapeutics (ARQT) Stock Statistics & Valuation Metrics
Total Valuation
Arcutis Biotherapeutics has a market cap or net worth of $4.03B. The enterprise value is $3.44B.
- Market Cap
- $4.03B
- Enterprise Value
- $3.44B
Share Statistics
Arcutis Biotherapeutics has 125,691,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 125,691,960
- Owned by Insiders
- 8.50%
- Owned by Institutions
- 42.22%
Financial Efficiency
Arcutis Biotherapeutics’s return on equity (ROE) is -0.09 and return on invested capital (ROIC) is -4.02%.
- Return on Equity (ROE)
- -0.09
- Return on Assets (ROA)
- -0.04
- Return on Invested Capital (ROIC)
- -4.02%
- Return on Capital Employed (ROCE)
- -0.04
- Revenue Per Employee
- 1.06M
- Profits Per Employee
- -45.60K
- Employee Count
- 354
- Asset Turnover
- 0.87
- Inventory Turnover
- 1.62
Valuation Ratios
The current PE Ratio of Arcutis Biotherapeutics is 141.58. Arcutis Biotherapeutics’s PEG ratio is 0.02.
- PE Ratio
- 141.58
- PS Ratio
- 8.47
- PB Ratio
- 18.50
- Price to FCF
- 100.36
- Price to Operating Cash Flow
- 103.80
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Arcutis Biotherapeutics had revenue of 376.07M and earned -16.14M in profits. Earnings per share was -0.13.
- Revenue
- 376.07M
- Gross Profit
- 339.38M
- Operating Income
- -12.23M
- Pretax Income
- -14.97M
- Net Income
- -16.14M
- EBITDA
- 1.78M
- Earnings Per Share (EPS)
- -0.13
Cash Flow
In the last 12 months, operating cash flow was 39.31M and capital expenditures -158,000, giving a free cash flow of 39.15M billion.
- Operating Cash Flow
- 39.31M
- Free Cash Flow
- 39.15M
- Free Cash Flow per Share
- 0.30
Dividends & Yields
Arcutis Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.99%
- Earnings Yield
- 0.69%
Stock Price Statistics
- Beta
- 0.70
- 52-Week Price Change
- 23.51%
- 50-Day Moving Average
- 26.64
- 200-Day Moving Average
- 25.22
- Relative Strength Index (RSI)
- 60.90
- Average Volume (3m)
- 2.50M
Important Dates
Arcutis Biotherapeutics upcoming earnings date is Nov 04, 2026, After Close (Not Confirmed).
- Last Earnings Date
- Aug 05, 2026
- Next Earnings Date
- Nov 04, 2026
- Ex-Dividend Date
- ―
Financial Position
Arcutis Biotherapeutics as a current ratio of 3.17, with Debt / Equity ratio of 3.31%
- Current Ratio
- 3.17
- Quick Ratio
- 2.99
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -20.58
- Interest Coverage Ratio
- -1.01
Taxes
In the past 12 months, Arcutis Biotherapeutics has paid 1.17M in taxes.
- Income Tax
- 1.17M
- Effective Tax Rate
- -0.08
Enterprise Valuation
Arcutis Biotherapeutics EV to EBITDA ratio is 93.10, with an EV/FCF ratio of 103.27.
- EV to Sales
- 8.71
- EV to EBITDA
- 93.10
- EV to Free Cash Flow
- 103.27
- EV to Operating Cash Flow
- 102.85
Balance Sheet
Arcutis Biotherapeutics has $238.55M in cash and marketable securities with $114.14M in debt, giving a net cash position of $124.42M billion.
- Cash & Marketable Securities
- $238.55M
- Total Debt
- $114.14M
- Net Cash
- $124.42M
- Net Cash Per Share
- $0.99
- Tangible Book Value Per Share
- $1.59
Margins
Gross margin is 91.14%, with operating margin of 7.38%, and net profit margin of 6.15%.
- Gross Margin
- 91.14%
- Operating Margin
- 7.38%
- Pretax Margin
- 6.31%
- Net Profit Margin
- 6.15%
- EBITDA Margin
- 9.36%
- EBIT Margin
- 8.88%
Analyst Forecast
The average price target for Arcutis Biotherapeutics is $39.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $39.83
- Price Target Upside
- 27.43% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 76.11%
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 6
- AI Score
- 73
